These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34156708)

  • 1. PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma.
    Song F; Jia M; Yu S; Cao L; Sun PL; Gao H
    Histopathology; 2021 Nov; 79(5):861-871. PubMed ID: 34156708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed death-ligand 1 expression in human papillomavirus-independent cervical adenocarcinoma and its prognostic significance.
    Chen L; Lucas E; Zhang X; Liu Q; Zhuang Y; Lin W; Chen H; Zhou F
    Histopathology; 2022 Jan; 80(2):338-347. PubMed ID: 34455625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix.
    Morgan S; Slodkowska E; Parra-Herran C; Mirkovic J
    Histopathology; 2019 Jun; 74(7):997-1004. PubMed ID: 30667073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 Expression in Endocervical Adenocarcinoma: Correlation With Patterns of Tumor Invasion, CD8+ Tumor-infiltrating Lymphocytes, and Clinical Outcomes.
    Rivera-Colon G; Chen H; Molberg K; Niu S; Strickland AL; Castrillon DH; Carrick K; Gwin K; Lea J; Zheng W; Lucas E
    Am J Surg Pathol; 2021 Jun; 45(6):742-752. PubMed ID: 33298732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prognostic Values of HPV Genotypes and Tumor PD-L1 Expression in Patients With HPV-associated Endocervical Adenocarcinoma.
    Zhou F; Chen H; Li M; Strickland AL; Zheng W; Zhang X
    Am J Surg Pathol; 2022 Mar; 46(3):300-308. PubMed ID: 35175967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
    Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
    Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
    Yamashita K; Iwatsuki M; Harada K; Eto K; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Ajani JA; Baba H
    Gastric Cancer; 2020 Jan; 23(1):95-104. PubMed ID: 31451991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 Expression and Tumour Microenvironment Patterns in Resected Non-Small-Cell Lung Cancer.
    Gurevičienė G; Matulionė J; Poškienė L; Miliauskas S; Žemaitis M
    Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541208
    [No Abstract]   [Full Text] [Related]  

  • 9. Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer.
    Enwere EK; Kornaga EN; Dean M; Koulis TA; Phan T; Kalantarian M; Köbel M; Ghatage P; Magliocco AM; Lees-Miller SP; Doll CM
    Mod Pathol; 2017 Apr; 30(4):577-586. PubMed ID: 28059093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 expression in ovarian clear cell carcinoma using the 22C3 pharmDx assay.
    Gao Y; Pan B; Jia H; Zhang Y; Wang S; Wang Y; Zhang S; Li M; Wang A; Wang X; Zhao K; Zhang Z; Sun J; Guo D; Liang Z
    Diagn Pathol; 2024 Jun; 19(1):82. PubMed ID: 38879528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer.
    Pereira MA; Ramos MFKP; Dias AR; Ribeiro R; Cardili L; Zilberstein B; Cecconello I; Ribeiro U; de Mello ES; de Castria TB
    Virchows Arch; 2021 Jun; 478(6):1039-1048. PubMed ID: 33098489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva.
    Czogalla B; Pham D; Trillsch F; Rottmann M; Gallwas J; Burges A; Mahner S; Kirchner T; Jeschke U; Mayr D; Schmoeckel E
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):569-577. PubMed ID: 32025868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 expression in sebaceous carcinomas.
    Saliba M; Shaheen M; Hajj RE; Abbas F; Bashir S; Sheikh UN; Mahfouz R; Loya A; Khalifeh I
    Cancer Immunol Immunother; 2021 Jul; 70(7):1907-1915. PubMed ID: 33398391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix.
    Heeren AM; Punt S; Bleeker MC; Gaarenstroom KN; van der Velden J; Kenter GG; de Gruijl TD; Jordanova ES
    Mod Pathol; 2016 Jul; 29(7):753-63. PubMed ID: 27056074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 and HLA-class I expression status and their therapeutic implication in oesophageal small-cell carcinoma.
    Yamashita S; Abe H; Yamashita H; Yagi K; Seto Y; Ushiku T
    Histopathology; 2023 Aug; 83(2):264-275. PubMed ID: 37071391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of Programmed Death Ligand 1 [PD-L1] and Mismatch Repair Status in Squamous Cell Carcinomas of Cervix.
    Anju G; Rao M; Elhence PA; Nalwa A; Singh P; Yadav G; Goel AD; Thiruvengadam D
    J Obstet Gynaecol India; 2024 Aug; 74(4):319-325. PubMed ID: 39280198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.
    Pasanen A; Ahvenainen T; Pellinen T; Vahteristo P; Loukovaara M; Bützow R
    Am J Surg Pathol; 2020 Feb; 44(2):174-181. PubMed ID: 31651527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological and immune characterization of mismatch repair deficient endocervical adenocarcinoma.
    Wu YW; Wei LJ; Yang X; Liang HY; Cai MY; Luo RZ; Liu LL
    Oncologist; 2024 Oct; 29(10):e1302-e1314. PubMed ID: 39110901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment in gastric adenocarcinoma.
    Patil PA; Blakely AM; Lombardo KA; Machan JT; Miner TJ; Wang LJ; Marwaha AS; Matoso A
    Histopathology; 2018 Jul; 73(1):124-136. PubMed ID: 29489025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 Expression and Silva Invasion Pattern in Villoglandular Adenocarcinoma of the Uterine Cervix.
    Dietl AK; Beckmann MW; Stuebs FA; Gass P; Emons J; Hartmann A; Erber R
    Int J Gynecol Pathol; 2024 Jul; 43(4):397-404. PubMed ID: 38293999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.